Related Experiment Video

Updated: May 2, 2026

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

13.2K

[Study of tolerance of central muscarinic receptor blockers]

M A Iudin, V N Bykov, A S Nikiforov

    Eksperimental'Naia I Klinicheskaia Farmakologiia
    |February 22, 2014
    PubMed

    Insights

    Five central muscarinic receptor antagonists were evaluated for tolerance in animal models. Benactizine and procyclidine demonstrated the highest safety margins, indicating superior tolerance in experimental settings.

    Area of Science:

    • Pharmacology
    • Neuroscience
    • Toxicology

    Context:

    • Central muscarinic receptor antagonists are crucial in treating various neurological and psychiatric disorders.
    • Understanding the differential tolerance of these antagonists is vital for optimizing therapeutic applications and minimizing adverse effects.
    • Previous research has focused on efficacy, with less emphasis on comparative safety profiles across different drug classes.

    Purpose:

    • To comparatively assess the tolerance and therapeutic index of five central muscarinic receptor antagonists in preclinical animal models.
    • To establish a toxicity ranking based on the orientation-exploratory reaction.
    • To determine the ratio of median toxic dose to median effective dose (TD50/ED50) for each antagonist in mice and rats.

    Summary:

    • The study ranked five muscarinic antagonists by increasing toxicity: procyclidine < trihexiphenidyl < benactizine < atropine < scopolamine, based on orientation-exploratory reactions.
    • In mice, trihexiphenidyl and benactizine showed the highest tolerance (TD50/ED50 > 10).
    • Benactizine and procyclidine exhibited maximum tolerance in rats (TD50/ED50 > 3), while trihexiphenidyl, atropine, and scopolamine had lower ratios (0.5-0.7).
    • Anticonvulsant activity varied, with scopolamine and atropine showing activity at 6.3x and 3.9x threshold doses, respectively, while procyclidine's anticonvulsant dose was lower than its threshold.

    Impact:

    • This research provides critical preclinical data on the relative safety of commonly used muscarinic antagonists.
    • Findings can guide the selection of antagonists with better safety profiles for specific therapeutic indications.
    • Highlights the importance of considering both efficacy and tolerance in drug development and clinical use.

    More Related Videos

    Quantifying Agonist Activity at G Protein-coupled Receptors11:45

    Quantifying Agonist Activity at G Protein-coupled Receptors

    Published on: December 26, 2011

    18.5K
    A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development07:02

    A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

    Published on: February 11, 2019

    10.0K

    Related Concept Videos

    Cholinergic Antagonists: Pharmacological Actions01:28

    Cholinergic Antagonists: Pharmacological Actions

    Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
    Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
    1.9K
    Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

    Antiasthma Drugs: Muscarinic Receptor Antagonists

    Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
    Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
    2.1K
    Cholinergic Antagonists: Pharmacokinetics01:24

    Cholinergic Antagonists: Pharmacokinetics

    Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
    1.1K
    Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

    Direct-Acting Cholinergic Agonists: Pharmacological Actions

    Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
    2.3K
    Cholinergic Receptors: Muscarinic01:25

    Cholinergic Receptors: Muscarinic

    The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
    The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
    4.9K
    Cholinergic Antagonists: Therapeutic Uses01:26

    Cholinergic Antagonists: Therapeutic Uses

    Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
    Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
    1.7K